Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

Greenstein et al. • 2021 • Oncotarget . 2021 Jun 22;12(13):1243-1255. doi: 10.18632/oncotarget.27989.

Adrenal tumors provide insight into the role of cortisol in NK cell activity

Greenstein et al. • 2021 • Endocr Relat Cancer . 2021 Jun 29;28(8):583-592. doi: 10.1530/ERC-21-0048.

Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid

Greenstein et al. • 2020 • AACR Annual Meeting 2020

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.

Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)

Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer

Munster et al. • 2019 •

Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.

Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.

Block et al. • 2017 • Cancer Manag Res. 2017;9:65-72.

Steroid receptors aplenty in prostate cancer.

Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.

“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.

Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.

Minireview: nuclear receptors and breast cancer.

Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.